307 related articles for article (PubMed ID: 37441075)
1. Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy.
Farhangnia P; Ghomi SM; Akbarpour M; Delbandi AA
Front Immunol; 2023; 14():1155778. PubMed ID: 37441075
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy.
Zhang T; Lin Y; Gao Q
Cancer Biol Med; 2023 Mar; 20(3):181-95. PubMed ID: 36971124
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment.
Lisi L; Lacal PM; Martire M; Navarra P; Graziani G
Pharmacol Res; 2022 Jan; 175():105997. PubMed ID: 34826600
[TBL] [Abstract][Full Text] [Related]
4. Anti-PD-L1-Based Bispecific Antibodies Targeting Co-Inhibitory and Co-Stimulatory Molecules for Cancer Immunotherapy.
Geng Q; Jiao P
Molecules; 2024 Jan; 29(2):. PubMed ID: 38257366
[TBL] [Abstract][Full Text] [Related]
5. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
6. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
7. Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies.
You G; Won J; Lee Y; Moon D; Park Y; Lee SH; Lee SW
Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358141
[TBL] [Abstract][Full Text] [Related]
8. Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1.
Chen W; Pandey M; Sun H; Rolong A; Cao M; Liu D; Wang J; Zeng L; Hunter A; Lin S
MAbs; 2021; 13(1):1914359. PubMed ID: 33870864
[TBL] [Abstract][Full Text] [Related]
9. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.
Poussin M; Sereno A; Wu X; Huang F; Manro J; Cao S; Carpenito C; Glasebrook A; Powell DJ; Demarest S
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253637
[TBL] [Abstract][Full Text] [Related]
10. Advances in the study of CD47-based bispecific antibody in cancer immunotherapy.
Zhang B; Li W; Fan D; Tian W; Zhou J; Ji Z; Song Y
Immunology; 2022 Sep; 167(1):15-27. PubMed ID: 35575882
[TBL] [Abstract][Full Text] [Related]
11. Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
Wei J; Yang Y; Wang G; Liu M
Front Immunol; 2022; 13():1035276. PubMed ID: 36389699
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison.
Cheng L; Chen L; Shi Y; Gu W; Ding W; Zheng X; Liu Y; Jiang J; Zheng Z
Mol Cancer; 2024 Apr; 23(1):77. PubMed ID: 38627681
[TBL] [Abstract][Full Text] [Related]
13. The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling.
Li T; Niu M; Zhou J; Wu K; Yi M
Cell Commun Signal; 2024 Mar; 22(1):179. PubMed ID: 38475778
[TBL] [Abstract][Full Text] [Related]
14. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials.
Hosseini SS; Khalili S; Baradaran B; Bidar N; Shahbazi MA; Mosafer J; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
Int J Biol Macromol; 2021 Jan; 167():1030-1047. PubMed ID: 33197478
[TBL] [Abstract][Full Text] [Related]
15. Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4- and PD-1-targeted immunotherapy.
Liu M; Wang X; Du X; Wu W; Zhang Y; Zhang P; Ai C; Devenport M; Su J; Muthana MM; Su L; Liu Y; Zheng P
Sci Transl Med; 2023 Mar; 15(685):eabm5663. PubMed ID: 36857433
[TBL] [Abstract][Full Text] [Related]
16. Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.
Lejeune M; Köse MC; Duray E; Einsele H; Beguin Y; Caers J
Front Immunol; 2020; 11():762. PubMed ID: 32457743
[TBL] [Abstract][Full Text] [Related]
17. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1123-1141. PubMed ID: 33788704
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint inhibition in pediatric hematologic malignancies.
Davis KL; Agarwal AM; Verma AR
Pediatr Hematol Oncol; 2017; 34(6-7):379-394. PubMed ID: 29190182
[TBL] [Abstract][Full Text] [Related]
19. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
20. The present and future of bispecific antibodies for cancer therapy.
Klein C; Brinkmann U; Reichert JM; Kontermann RE
Nat Rev Drug Discov; 2024 Apr; 23(4):301-319. PubMed ID: 38448606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
